Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer.

Next Previous
Trial Profile

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tasquinimod (Primary) ; Cabazitaxel; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Acronyms CATCH

Most Recent Events

  • 16 Apr 2015 After an interim analysis of the phase III 10TASQ10 study showed that tasquinimod did not improve overall survival, and efficacy results together with preliminary safety data did not support a positive benefit-risk balance in this population, Active Biotech and Ipsen announced their decision to discontinue the development of tasquinimod in prostate cancer, according to a media release.
  • 16 Apr 2015 Status changed from recruiting to discontinued, according to a media release from Active Biotech and Ipsen.
  • 14 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2015 to 1 Jun 2016.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top